Literature DB >> 20374348

Prevalence of anti cyclic citrullinated peptide antibodies in Malaysian rheumatoid arthritis patients and its correlation with disease activity.

Sargunan Sockalingam1, Chow Sook Khuan, Pavai Sthaneshwar.   

Abstract

AIM: The objectives of this study are to provide data regarding the prevalence of anti-cyclic citrullinated peptide (CCP) antibodies in Malaysian rheumatoid arthritis (RA) patients and to correlate the levels of anti-CCP antibody with the Disease Activity Score (DAS).
METHOD: We studied the prevalence of anti-CCP antibodies in 51 RA patients attending our clinic and 29 controls. We also looked for correlation between anti-CCP antibody levels with the DAS and parameters such as duration of disease, rheumatoid factor (RF) and disease-modifying anti rheumatic drug (DMARD) usage.
RESULTS: None of the controls demonstrated anti-CCP antibodies. Forty-one out of 51 patients (80.4%) were positive for anti-CCP antibodies. Sensitivity and specificity were 80.4% and 100% respectively in this study. Anti-CCP levels correlated significantly with rheumatoid factor, but no correlation was observed with the other parameters.
CONCLUSIONS: Anti-CCP antibody is prevalent in Malaysian RA patients at 80.4% and more sensitive than RF in our cohort of established RA patients. Even though the anti-CCP levels correlated with RF, it did not show correlation with DAS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20374348     DOI: 10.1111/j.1756-185X.2009.01412.x

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  6 in total

1.  Discriminative and diagnostic value of anti-cyclic citrullinated peptide antibodies in Iranian patients with rheumatoid arthritis.

Authors:  Jamileh Moghimi; Raheb Ghorbani; Farnaz Hasani; Mehrdad Sheikhvatan
Journal:  Rheumatol Int       Date:  2012-04-03       Impact factor: 2.631

2.  Correlation of Demographic and Clinical Characteristics with Rheumatoid Factor Seropositivity in Rheumatoid Arthritis Patients.

Authors:  Maizatul Akmal Othman; Wan Syamimee Wan Ghazali; Nurul Khaiza Yahya; Kah Keng Wong
Journal:  Malays J Med Sci       Date:  2016-12-07

3.  Anti-cyclic citrullinated peptide antibody is a good indicator for the diagnosis of rheumatoid arthritis.

Authors:  Asrul Abdul Wahab; Marlyn Mohammad; M M Rahman; Mohd Shahrir Mohamed Said
Journal:  Pak J Med Sci       Date:  2013-05       Impact factor: 1.088

4.  Anti-Cyclic Citrullinated Peptide Antibody and Periodontal Status in Rheumatoid Arthritis Patients.

Authors:  Wan Majdiah Wan Mohamad; Soh Ke Jia; Wan Syamimee Wan Ghazali; Haslina Taib
Journal:  Pak J Med Sci       Date:  2018 Jul-Aug       Impact factor: 1.088

5.  Anti-cyclic citrullinated peptide antibody is highly associated with rheumatoid factor and radiological defects in rheumatoid arthritis patients.

Authors:  Farah Nadiah Sulaiman; Kah Keng Wong; Wan Aireene Wan Ahmad; Wan Syamimee Wan Ghazali
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

6.  Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis.

Authors:  Nadia M T Roodenrijs; Melinda Kedves; Attila Hamar; György Nagy; Jacob M van Laar; Désirée van der Heijde; Paco M J Welsing
Journal:  RMD Open       Date:  2021-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.